Early relapses after adjuvant chemotherapy suggests primary chemoresistance in diffuse gastric cancer.

ABSTRACT:

Background

Survival from gastric cancer remains poor, particularly in Western populations. Previous pre-clinical and subgroup analyses of clinical trials have suggested differing benefits from fluoropyrimidine-based chemotherapeutics for diffuse and intestinal gastric cancer. This analysis examines patterns of relapse with and without adjuvant chemotherapy after curative resection for gastric cancer in these subtypes to explore the Lauren classification as a predictive marker of benefit for fluoropyrimidine-based adjuvant chemotherapy.

Patients and methods

Gastric cancer patients enrolled in an ongoing tissue banking study were analysed, 164 patients who would currently be considered for adjuvant therapy after curative resection were included in the analysis. Patients who di

SUBMITTER: Pattison S 

PROVIDER: S-EPMC5602536 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature